171 related articles for article (PubMed ID: 24950688)
1. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
[TBL] [Abstract][Full Text] [Related]
2. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
Khan S; Weterings JJ; Britten CM; de Jong AR; Graafland D; Melief CJ; van der Burg SH; van der Marel G; Overkleeft HS; Filippov DV; Ossendorp F
Mol Immunol; 2009 Mar; 46(6):1084-91. PubMed ID: 19027958
[TBL] [Abstract][Full Text] [Related]
3. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
4. Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients.
Dou Y; Jansen DTSL; van den Bosch A; de Man RA; van Montfoort N; Araman C; van Kasteren SI; Zom GG; Krebber WJ; Melief CJM; Woltman AM; Buschow SI
Antiviral Res; 2020 Jun; 178():104746. PubMed ID: 32081741
[TBL] [Abstract][Full Text] [Related]
5. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.
Zom GG; Welters MJ; Loof NM; Goedemans R; Lougheed S; Valentijn RR; Zandvliet ML; Meeuwenoord NJ; Melief CJ; de Gruijl TD; Van der Marel GA; Filippov DV; Ossendorp F; Van der Burg SH
Oncotarget; 2016 Oct; 7(41):67087-67100. PubMed ID: 27564262
[TBL] [Abstract][Full Text] [Related]
6. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG; Wiesmüller KH; Chandran PA; Zelba H; Rusch E; Gouttefangeas C; Kowalewski DJ; Di Marco M; Haen SP; Walz JS; Gloria YC; Bödder J; Schertel JM; Tunger A; Müller L; Kießler M; Wehner R; Schmitz M; Jakobi M; Schneiderhan-Marra N; Klein R; Laske K; Artzner K; Backert L; Schuster H; Schwenck J; Weber ANR; Pichler BJ; Kneilling M; la Fougère C; Forchhammer S; Metzler G; Bauer J; Weide B; Schippert W; Stevanović S; Löffler MW
J Immunother Cancer; 2019 Nov; 7(1):307. PubMed ID: 31730025
[TBL] [Abstract][Full Text] [Related]
7. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
8. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.
Khan S; Bijker MS; Weterings JJ; Tanke HJ; Adema GJ; van Hall T; Drijfhout JW; Melief CJ; Overkleeft HS; van der Marel GA; Filippov DV; van der Burg SH; Ossendorp F
J Biol Chem; 2007 Jul; 282(29):21145-59. PubMed ID: 17462991
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells.
Skabytska Y; Wölbing F; Günther C; Köberle M; Kaesler S; Chen KM; Guenova E; Demircioglu D; Kempf WE; Volz T; Rammensee HG; Schaller M; Röcken M; Götz F; Biedermann T
Immunity; 2014 Nov; 41(5):762-75. PubMed ID: 25456159
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
11. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
12. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
13. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
[TBL] [Abstract][Full Text] [Related]
14. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
15. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
Derouazi M; Di Berardino-Besson W; Belnoue E; Hoepner S; Walther R; Benkhoucha M; Teta P; Dufour Y; Yacoub Maroun C; Salazar AM; Martinvalet D; Dietrich PY; Walker PR
Cancer Res; 2015 Aug; 75(15):3020-31. PubMed ID: 26116496
[TBL] [Abstract][Full Text] [Related]
16. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling.
Maruyama A; Shime H; Takeda Y; Azuma M; Matsumoto M; Seya T
Biochem Biophys Res Commun; 2015 Feb; 457(3):445-50. PubMed ID: 25596131
[TBL] [Abstract][Full Text] [Related]
17. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines.
Tyne AS; Chan JG; Shanahan ER; Atmosukarto I; Chan HK; Britton WJ; West NP
Vaccine; 2013 Sep; 31(40):4322-9. PubMed ID: 23880366
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
